Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GHRS |
---|---|---|
09:32 ET | 1132 | 8.8 |
09:37 ET | 1100 | 8.8 |
09:39 ET | 300 | 8.8 |
09:48 ET | 318 | 9.1 |
09:51 ET | 500 | 9.14 |
10:00 ET | 1000 | 9.2 |
10:02 ET | 100 | 9.18 |
10:13 ET | 1315 | 9 |
10:15 ET | 100 | 8.9 |
10:20 ET | 100 | 8.9 |
10:24 ET | 160 | 8.89 |
10:26 ET | 100 | 8.635 |
10:27 ET | 300 | 8.86 |
10:29 ET | 583 | 8.9 |
10:45 ET | 300 | 9.02 |
11:02 ET | 400 | 8.8334 |
11:03 ET | 100 | 8.85 |
11:30 ET | 150 | 8.98 |
11:32 ET | 331 | 8.6213 |
11:34 ET | 100 | 8.85 |
11:48 ET | 100 | 8.75 |
12:01 ET | 600 | 8.8 |
12:28 ET | 272 | 8.79 |
12:57 ET | 338 | 8.81 |
01:02 ET | 2306 | 9 |
01:04 ET | 1103 | 9.31 |
01:06 ET | 251 | 9.5437 |
01:11 ET | 100 | 9.365 |
01:13 ET | 152 | 9.2767 |
01:44 ET | 100 | 9.355 |
01:47 ET | 302 | 9.05 |
01:51 ET | 600 | 9.03 |
01:54 ET | 3767 | 8.7 |
01:56 ET | 103 | 8.84 |
01:58 ET | 2426 | 8.8966 |
02:02 ET | 1200 | 8.73 |
02:12 ET | 100 | 8.905 |
02:14 ET | 100 | 8.79 |
02:18 ET | 200 | 8.75 |
02:25 ET | 2200 | 8.7 |
02:27 ET | 200 | 8.735 |
02:34 ET | 100 | 8.56 |
02:45 ET | 100 | 8.87 |
03:15 ET | 100 | 8.7 |
03:32 ET | 100 | 8.9 |
03:35 ET | 100 | 8.68 |
03:46 ET | 3442 | 8.73 |
03:48 ET | 200 | 8.715 |
03:50 ET | 11900 | 8.675 |
03:51 ET | 20345 | 8.7821 |
03:53 ET | 100 | 8.56 |
03:57 ET | 200 | 8.675 |
04:00 ET | 45212 | 8.62 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
GH Research PLC | 448.5M | 0.0x | --- |
Lexicon Pharmaceuticals Inc | 469.9M | -1.7x | --- |
Kalvista Pharmaceuticals Inc | 483.1M | -3.2x | --- |
Prime Medicine Inc | 492.1M | -1.9x | --- |
Absci Corp | 457.6M | -4.3x | --- |
PureTech Health PLC | 483.5M | -6.9x | --- |
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $448.5M |
---|---|
Revenue (TTM) | --- |
Shares Outstanding | 52.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.76 |
EPS | --- |
Book Value | $4.21 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.